Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

German Biopharmaceutical Partners to Seek Osteoarthritis Drug

By BiotechDaily International staff writers
Posted on 02 Dec 2013
Two German biopharmaceutical companies are joining forces to develop a new class of drugs for treatment of osteoarthritis.

At the present time there are no truly effective treatments for osteoarthritis of the knee, which, according to the World Health Organization, effects more than 5% of adults over the age of 40 (more than 30 million people) in the developed countries.

To boost the search for drugs to treat osteoarthritis, Biopharm GmbH (Heidelberg, Germany) and Merck Serono (Darmstadt, Germany) have agreed to embark on a two-year joint discovery program focused on a potential pro-anabolic osteoarthritis modifying drug based on a growth factor derived from Biopharm's growth factor platform technology.

According to the terms of the agreement, Biopharm will provide variants of a wild type protein, which is thought to drive hyaline joint cartilage formation during embryogenesis and seems to be associated with osteoarthritis, as well as early preclinical research services. In the event of identification of potential development candidates, Merck Serono will own exclusive development and commercialization rights.

“We have insight that the maternal protein shows an important role in joint cartilage formation. These findings raise hope that a modified wild type protein may induce cartilage regeneration in the osteoarthritic joint,” said Dr. Frank Plöger, CSO of Biopharm. “The alliance will draw on the combined expertise and resources of Merck Serono and Biopharm with the ultimate goal to develop a disease modifying osteoarthritis drug. Although we have knowledge about the molecule, we need a partner like Merck Serono, who does not only provide the necessary resources, but also know how best to set up of our research program to ensure a successful hand over to clinical experts.”

Related Links:

Biopharm GmbH
Merck Serono



Channels

Genomics/Proteomics

view channel
Image: The photomicrograph shows the head of a mouse embryo in which the pericytes are visible as blue dots along the blood vessel (Photo courtesy of the University of Gothenburg).

Genetically Engineered Mouse Model Reveals Key to Formation of the Blood-Brain Barrier

Use of a mouse model that had been genetically engineered to lack the gene that encodes the forkhead transcription factor Foxf2 has helped to explain how pericytes, cells that line the capillaries, form... Read more

Drug Discovery

view channel
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).

Novel Controlled-Release Drug Delivery System Heals Spinal Inflammation in Mouse Model

A novel drug delivery system that allows controllable release of an anti-inflammatory agent directly to the site of inflammation or injury was tested successfully in a mouse model. Investigators at... Read more

Therapeutics

view channel
Image: A photmicrograph of medium spiny neurons (yellow) with nuclear inclusions (orange), which occur as part of the Huntington\'s disease process. Several neurons are colored yellow and have a large central core with up to two dozen tendrils branching out of them. The core of the neuron in the foreground contains an orange blob about a quarter of its diameter (Photo courtesy of Wikimedia Commons).

Seeding Assay May Boost Search for Huntington's Disease Drugs

An assay technique that measures seeding of mutant huntingtin aggregates in cerebral spinal fluid (CSF) may identify individuals with Huntington's disease (HD) that have not yet become symptomatic and... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.